Profil
Karim Dabbagh is the founder of Modus Biomedicine, Inc. which was founded in 2009.
He held the title of Chief Executive Officer from 2009 to 2010.
Dr. Dabbagh is currently the Independent Chairman at Maat Pharma SA since 2023.
Previously, he worked at Second Genome, Inc. from 2014 to 2023, where he held the titles of President, Chief Executive Officer & Director from 2018 to 2023.
Dr. Dabbagh completed his undergraduate degree at Imperial College London and his doctorate at University College London.
Aktive Positionen von Karim Dabbagh
| Unternehmen | Position | Beginn |
|---|---|---|
| MAAT PHARMA | Vorsitzender | 21.06.2023 |
Ehemalige bekannte Positionen von Karim Dabbagh
| Unternehmen | Position | Ende |
|---|---|---|
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | Vorstandsvorsitzender | 01.09.2023 |
| Modus Biomedicine, Inc. | Vorstandsvorsitzender | 01.12.2010 |
Ausbildung von Karim Dabbagh
| University College London | Doctorate Degree |
| Imperial College London | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MAAT PHARMA | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | Health Technology |
| Modus Biomedicine, Inc. |
